XANTHO Bio Seeks International Licensing, Initiates Phase 2b Clinical Trial
To actively seek international licensing and partnership opportunities for conducting a Phase 2b clinical trial, our company continued to participate in US Bio in 2025.
This year, the international biotech event was held in Boston, USA, where we engaged with and held discussions with many global pharmaceutical companies.
During the exhibition, our colleagues were also interviewed by Global Bio & Investment, a Taiwanese media outlet specializing in biotechnology industry news, to share that our self-developed botanical new drug-GM-XANTHO has completed its Phase 2a clinical trial.
Please refer to the full interview for more details. 👉Global Bio and Investment
Disclaimer
This article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change.
